Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Triple-negative breast cancer (TNBC) presents significant challenges due to aggressive progression and limited treatment options.
• Selumetinib, a MEK1/2 inhibitor, shows efficacy against various malignancies, suggesting potential for TNBC treatment.

Purpose of the Study:

• To investigate the potential of Selumetinib as a therapeutic agent for triple-negative breast cancer.
• To elucidate the underlying molecular mechanisms of Selumetinib's action in TNBC.

Main Methods:

• Cell viability, apoptosis, and migration assays (MTT, TUNEL, wound-healing, Transwell, FCM) were performed on TNBC cell lines (HCC1937, MDA-MB-231) treated with Selumetinib.
• MicroRNA (miRNA) array analysis identified changes in miRNA expression. Luciferase reporter assays and siRNA were used to validate the miR-302a/CUL1 interaction and CUL1's role.
• Functional studies involved transfecting cells with miR-302a antagomirs and CUL1-overexpressing plasmids alongside Selumetinib treatment.

Main Results:

• Selumetinib significantly reduced proliferation and migration, induced apoptosis, and caused G1 arrest in TNBC cells.
• Treatment with Selumetinib led to the upregulation of miR-302a, which subsequently inhibited CUL1 expression.
• CUL1 negatively regulated its downstream targets, TIMP1 and TRAF2. Knockdown of miR-302a or overexpression of CUL1 reversed Selumetinib's cytotoxic effects.

Conclusions:

• MiR-302a directly targets and regulates CUL1 expression in TNBC.
• The miR-302a/CUL1 axis is a key mediator of Selumetinib-induced cytotoxicity in triple-negative breast cancer, highlighting a novel therapeutic pathway.